NL-OMON36196
Completed
Not Applicable
A phase I, mono-center, randomized, placebo and comparator controlled, single blind, rising dose, clinical study to determine single dose pharmacokinetics, pharmacodynamics, safety and tolerability of four doses of FSH-GEX* according to adaptive design (25, 75, 150 and 300 IU) administered subcutaneously in healthy pituitary-suppressed female volunteers - GEXGP24101
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Infertility
- Sponsor
- Glycotope GmbH
- Enrollment
- 18
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy female subjects
Exclusion Criteria
- •Clinical significant abnormalities at screening
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase I, single-centre, randomised, placebo-controlled, double-blinded study, with single ascending dose and multiple dose at maximum tolerated dose, evaluating the safety, tolerability and pharmacokinetics of ALX-0171, administered by pulmonary inhalation, in healthy male volunteersrespiratory syncytial virus infectionvirus that infect the airways1004743810024970NL-OMON37342Ablynx NV100
Completed
Not Applicable
Phase I, Single-Center, Randomized, Placebo-Controlled, Double-Blinded Study with Single Ascending Doses, Evaluating the Safety and Tolerability of T20K, Administered by a 1-hr IV Infusion in Healthy Male VolunteersNL-OMON48273Cyxone AB40
Completed
Phase 1
A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy VolunteersChronic PainACTRN12617001330336Xgene Pharmaceutical Inc.50
Active, not recruiting
Phase 1
A Phase I/II, randomised, multicentre, placebo-controlled, partially-blinded, parallel-group study to assess the safety, tolerability and immune response following vaccination with ImmunoseTM FLU in older adults (age 50 to 75 years)InfluenzaMedDRA version: 20.0 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2017-004376-64-SEEurocine Vaccines AB300
Completed
Not Applicable
A Phase 1, Single-Center, Single-Blind, Placebo and Propofol Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous (IV) Infusion Doses of ABP-700anesthesiaNot applicableNL-OMON41980Annovation Biopharma, Inc. (a wholly owned subsidiary of The Medicines Company, Inc.)72